Improving treatment for acute myeloid leukemia using targeted immunotherapy
Official title: Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders
Funded at Fred Hutchinson Cancer Center · NIH-10906142 · Data updated 2026-11-12
This study is looking at new ways to make immunotherapy better and safer for people with acute myeloid leukemia (AML) by developing special antibodies that target a protein called CD33, and it aims to help improve treatment results while protecting healthy cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $161,878 |
| NIH project number | 5R50CA274319-02 |
| Project ID | NIH-10906142 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or other conditions that express the CD33 protein.
✕Less likely to help
Patients without CD33-positive disorders or those who have not been diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness and safety of immunotherapy that targets CD33, a protein found on certain blood cells, particularly in patients with acute myeloid leukemia (AML). The team is developing new human antibodies that can target different parts of the CD33 protein, aiming to improve treatment outcomes. They will conduct laboratory studies to test these new therapies, including a method that uses radiation to specifically attack cancer cells while minimizing harm to normal cells. The ultimate goal is to translate these findings into clinical applications that can benefit patients directly.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with acute myeloid leukemia and other related disorders.
How similar studies have gone: Previous research has shown promise in targeting CD33 for AML treatment, but this approach with new antibodies and radioimmunotherapy is relatively novel.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Laszlo, George S — Fred Hutchinson Cancer Center
- Study coordinator: Laszlo, George S
Related research
Other NIH-funded projects on the same topics.
-
CD33-targeted immunotherapy to help AML patients
A patient-focused approach tests new antibody-drug strategies that target CD33 to improve safety and effectiveness for AML patients.
-
Myeloid-targeted oligonucleotide STAT3 blocker with TMLI for AML treatment
A new approach combines targeted radiation with a special gene-silencing treatment to help people with treatment-refractory acute myeloid leukemia.
-
Better CD33-targeted treatments for acute myeloid leukemia
Researchers are developing new CD33-targeted antibody therapies paired with a potent alpha-particle agent to help people with acute myeloid leukemia.
-
Improving treatment for acute myeloid leukemia with targeted radiation and immune therapy
This work explores a new way to treat acute myeloid leukemia that has been difficult to cure, by combining a special type of radiation with a targeted immune therapy.
-
Targeting specific immune cells to improve treatment for acute myeloid leukemia
This study is testing a new way to treat acute myeloid leukemia (AML) by using a special combination of targeted treatments that block a protein called STAT3 along with a type of radiation therapy, to see if it can help improve survival for patients whose cancer hasn't responded to other treatments.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.